UroGen Pharma to Report Third Quarter Financial Results on Wednesday, November 6, 2024
30 Outubro 2024 - 9:00AM
Business Wire
Conference Call and Webcast Scheduled for
Wednesday, November 6, 2024, at 10:00AM ET
UroGen Pharma Ltd. (Nasdaq:URGN), a biotech company dedicated to
developing and commercializing innovative solutions that treat
urothelial and specialty cancers, today announced that it will
report 2024 third quarter financial results on Wednesday, November
6, 2024, prior to the open of the stock market. The announcement
will be followed by a live audio webcast and conference call at
10:00 AM Eastern Time.
A live public webcast of the earnings conference call can be
accessed on UroGen’s Investor Relations website. Following the live
webcast, a replay will be available on the site for approximately
30 days.
About UroGen Pharma Ltd.
UroGen is a biotech company dedicated to developing and
commercializing innovative solutions that treat urothelial and
specialty cancers because patients deserve better options. UroGen
has developed RTGel® reverse-thermal hydrogel, a proprietary
sustained-release, hydrogel-based platform technology that has the
potential to improve the therapeutic profiles of existing drugs.
UroGen’s sustained release technology is designed to enable longer
exposure of the urinary tract tissue to medications, making local
therapy a potentially more effective treatment option. Our first
product to treat low-grade upper tract urothelial cancer and
investigational treatment UGN-102 (mitomycin) for intravesical
solution for patients with LG-IR-NMIBC are designed to ablate
tumors by non-surgical means. UroGen is headquartered in Princeton,
NJ with operations in Israel. Visit www.UroGen.com to learn more or
follow us on X (Twitter), @UroGenPharma.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241030832940/en/
INVESTORS: Vincent Perrone Senior Director, Investor Relations
vincent.perrone@urogen.com 609-460-3588 ext. 1093
MEDIA: Cindy Romano Director, Corporate Communications
cindy.romano@urogen.com 609-460-3583 ext. 1083
UroGen Pharma (NASDAQ:URGN)
Gráfico Histórico do Ativo
De Out 2024 até Nov 2024
UroGen Pharma (NASDAQ:URGN)
Gráfico Histórico do Ativo
De Nov 2023 até Nov 2024
